Abstract
To examine the antiparkinsonian effects of blocking glycineB receptors, we designed a pilot study testing the potent and selective antagonist, PAMQX, in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. PAMQX had no intrinsic effects but markedly potentiated the antiparkinsonian action of levodopa. In a dose-dependent fashion, coadministration of the glycineB antagonist with levodopa extended the response duration by nearly 60%. It is noteworthy that PAMQX, within a considerable dose range, did not cause ataxia or other side effects. These data indicate that blocking N-methyl-D-aspartate receptors selectively to manipulate dopaminergic-mediated motor responses may be produced effectively by glycineB antagonists.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Animals
-
Antiparkinson Agents / administration & dosage
-
Antiparkinson Agents / therapeutic use*
-
Behavior, Animal
-
Disability Evaluation
-
Disease Models, Animal
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Glycine Agents / administration & dosage*
-
Levodopa / administration & dosage
-
Levodopa / therapeutic use*
-
Macaca mulatta
-
Motor Activity / drug effects
-
Parkinsonian Disorders / chemically induced
-
Parkinsonian Disorders / drug therapy*
-
Pilot Projects
-
Psychomotor Performance / drug effects
-
Receptors, Glycine / antagonists & inhibitors*
Substances
-
Antiparkinson Agents
-
Glycine Agents
-
Receptors, Glycine
-
Levodopa
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine